Reuters: Charity attacks Gilead over hepatitis C drug restrictions
“Charity Médecins Sans Frontières has accused U.S. drugmaker Gilead Sciences Inc. of restricting access to its breakthrough hepatitis C drug Sovaldi in developing countries as it tries to protect profit margin in wealthier nations. MSF, also known as Doctors Without Borders, said Gilead’s restrictions aimed to stop discounted supplies of Sovaldi being diverted to patients from rich countries, but that the effort had resulted in ‘multiple restrictions and demands’ on people receiving treatment in poor countries…” (Siddiqui/Berkrot, 3/18).